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disease areas and therapeutic classes, but treatments for musculoskeletal and 
rheumatic disease are evaluated most frequently.  
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OBJECTIVES: Studies of health outcomes commonly involve binary measures, 
assessed multiple times. Although generalized linear mixed (GLIMMIX) models 
are well suited for analyzing these data, there does not exist a formal statistic to 
assess the goodness of fit (GOF) for GLIMMIX models. We developed an extension 
of the Hosmer-Lemeshow GOF test used for logistic regression that can be 
applied to GLIMMIX models. METHODS: The correlation among repeated 
measurements of the binary outcome variable was accounted for by a random 
effect in the GLIMMIX model. The principles of Hosmer-Lemeshow method were 
followed. The linear unbiased estimate of dependent variables were transformed 
to the original probability, sorted from least to largest, and divided into deciles. A 
Chi-square statistic and corresponding p-value with eight degrees of freedom, 
was calculated based upon the expected and observed numbers among deciles. 
The proposed GOF test was validated by a simulation study with 1000 runs 
generated from logistic regression models with and without random effects. The 
results were compared with the Hosmer-Lemeshow GOF test in situations where 
the latter is appropriate. The proposed method was used in the analysis of a 
comparative effectiveness (CE) study of ophthalmologic treatments for open-
angle glaucoma patients. RESULTS: When there was no random effect, the 
proposed GOF test results from the GLIMMIX procedure were almost identical to 
those of Hosmer-Lemeshow GOF test from the logistic procedure. With a random 
effect built in a correctly specified model, the goodness of fit rejection rate was 
5.1%, which is close to the nominal level 5%. The proposed test did not indicate 
lack of fit for the regression models in the CE study. CONCLUSIONS: The 
proposed GOF test provides an assessment of model fit for models with binary 
outcomes and repeated measurements for predictor variables.  
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OBJECTIVES: Amiodarone, a frequently used drug for AF patients, has been 
associated with severe adverse events. A relatively new drug, dronedarone, has 
been shown to reduce the risk of adverse events and duration of hospital stays in 
AF patients. The objective of this study was to assess the annual health care 
charges and utilization in AF patients on dronedarone compared to amiodarone. 
METHODS: Data from the University of Utah Enterprise Data Warehouse were 
analyzed for AF patients from October 2009 to October 2012. Eligible patients had 
a prescription for either amiodarone or dronedarone on index date; had 6 
months pre-index and 12 months post-index follow-up activity. Annual total 
charges and annual inpatient and outpatient visits were assessed during the 
follow-up period. Generalized linear model (GLM) with gamma distribution and 
log link and negative binomial model (NBM) were used to examine the annual 
charges and usage between the two groups, respectively, controlling for 
demographics, insurance status, baseline comorbidities, and prior drug use. 
RESULTS: Of the 1003 patients analyzed, 134 (13.4%) patients were prescribed 
dronedarone and 869 (86.6%) were prescribed amiodarone. The age and gender 
distribution was not significantly different between the two groups (p>0.05). The 
mean unadjusted annual health care charges for dronedarone were significantly 
lower compared to amiodarone ($40,395 vs. $96,387, p<0.05). The mean annual 
outpatient visits for dronedarone were significantly higher compared to 
amiodarone (7.96 vs. 4.78, p<0.05). GLM results indicate that dronedarone 
patients had 71% lower annual health care charges compared to amiodarone 
patients (coeff. -0.711, p<0.05). NBM results show that dronedarone patients were 
61% less likely to have inpatient visits (coeff. -0.61, p<0.05) and 39% more likely 
to have outpatient visits (coeff. 0.39, p<0.05) compared to amiodarone patients. 
CONCLUSIONS: The annual health care charges and inpatient visits were 
significantly lower but outpatient utilization was higher in dronedarone 
compared to amiodarone patients.  
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OBJECTIVES: When comparing survival time among competing treatments, the 
assumption of constant hazards, necessary for use of semi-parametric modeling 
techniques, cannot always be met. Use of a fully parametric model provides a 
more flexible approach and a better estimate of treatment effects. Using the 
results of our already published network meta-analysis, our objective is to focus 
on the use of parametric survival curves to estimate progression free survival 
(PFS) in patients with chronic lymphocytic leukemia. METHODS: We tested 
parametric Weibull and log-logistic regression models with a two-parameter 
relative treatment effect (scale and shape), to indirectly compare PFS from 
multiple trials. We scanned survival curves from each included study, and used 
data from each consecutive interval to calculate model parameters. We 
estimated the number of deaths using the binomial likelihood distribution. We 
conducted the network meta-analysis using Bayesian statistical methods. We fit 
fixed and random effects models, and modeled scale and shape parameters on 
the log hazard scale. We evaluated goodness-of-fit by visually inspecting the 
linearity of diagnostic plots and comparing deviance information criteria (DIC). 
Using parameter estimates from the posterior summary we derived hazard rates, 
hazard ratios (HRs) and PFS survival curves for each treatment. To estimate the 
mean duration of PFS for each treatment, we calculated the area under each PFS 
curve. RESULTS: Seven randomized controlled trials of five treatments were 
included. The fixed effects Weibull model was the best fit for the data, with 
stronger linearity in the diagnostic plots and a lower DIC value. Hazard rates, 
HRs, PFS, survival, and median survival, with 95% credible intervals, were 
calculated for each treatment. Results suggest the hazard of disease progression 
for two treatments was constant, and increased over time for the other three. 
CONCLUSIONS: Parametric survival methods are useful in comparing PFS in the 
oncology setting.  
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OBJECTIVES: A traditional statistical measure such as concordance(c) statistics 
has been used widely for comparison of risk adjustment models; however, c-
statistic has been criticized for its insensitivity. To overcome the limitations of c-
statistics, novel reclassification measures (reclassification calibration statistics, 
Net Reclassification Index (NRI) and Integrated Discrimination Index (IDI)) have 
recently been proposed. The objective was to compare Charlson Comorbidity 
Index (CCI), Chronic Disease Score (CDS) and CCI+CDS in predicting one year 
mortality in type-2 diabetes mellitus patients (T2DM) by applying novel 
reclassification measures. METHODS: The Clinical Practice Research Database, 
electronic medical record data from UK, was used for this retrospective 
longitudinal cohort study. Patients diagnosed with T2DM from January 1, 2006 to 
December 31, 2006 were included. Diagnosis and prescription information upto 
1-year prior to the index date, i.e. first date of T2DM diagnosis, was used to 
create CCI and CDS, respectively. Patients were followed for 1 year from the 
index date to observe mortality. Descriptive statistics was used to describe the 
study cohort. In addition to traditional c-statistics from logistics regression, NRI 
and IDI were used to compare risk adjustment models. RESULTS: The cohort 
consisted of 26,191 patients with T2DM. The mean CCI and CDS were 0.24±0.67 
and 1.58±1.06, respectively. The c-statistics values for CCI, CDS and CCI+CDS 
models were 0.791 (95%CI: 0.777-0.805), 0.788 (95%CI: 0.774-0.802) and 0.803 
(95%CI: 0.789-0.817), respectively. The CDS and CCI+CDS reclassified 1.92% 
(p=0.238) and 6.50% (p=<0.001) patients into correct strata compared to the  
CCI. The IDI values for CDS and CCI+CDS were -0.64% (p=<0.001) and 0.43 
(p=<0.001). This means that addition of CDS in CCI improved the prediction of 
mortality. CONCLUSIONS: Combined score (CCI + CDS) performed better than 
individual scores. In addition to c-statistics, reclassification measures such as 
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OBJECTIVES: When indirectly comparing treatments across separate clinical 
trials, matching-adjusted indirect comparisons (MAICs) can help avoid bias due 
to cross-trial differences in baseline characteristics. The approach uses 
propensity scores to adjust individual patient data from trials of one treatment 
to match published baseline characteristics from trials of comparator 
treatments. We assessed the statistical properties of MAIC, including the 
accuracy of estimated treatment effects and their standard errors, in a 
simulation study. METHODS: Each simulation scenario included two randomized 
controlled trials with a common control arm and a dichotomous outcome. 
Sample sizes ranged from 125 to 1000 patients per arm. Cross-trial differences in 
baseline characteristics were simulated to generate low, moderate and high 
levels of potential bias. For each simulated dataset, MAIC was used to estimate 
the relative treatment effect using individual patient data from one trial and 
aggregate data from the other. Estimated treatment effects and standard errors 
were evaluated for accuracy across 1000 simulations. Indirect comparisons 
without matching adjustment were evaluated in parallel. RESULTS: By design, 
indirect comparisons without matching exhibited biases ranging from 10% to 
200% of the true treatment effect across simulation scenarios. In contrast, the 
MAIC estimators exhibited negligible bias, falling within +/- 2% of the true 
treatment effect when all confounding variables were considered. The sandwich 
estimator closely approximated the true standard errors, and was slightly 
conservative, overestimating by as much as 8%, but usually less than 5%. These 
findings were consistent across the range of investigated sample sizes and levels 
of confounding. CONCLUSIONS: MAIC can remove bias due to observed cross-
trial differences and provide reliable assessments of statistical uncertainty for 
indirect comparisons that combine individual patient data and aggregate data.  
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OBJECTIVES: Separation problems (perfect prediction of a binary outcome by one 
or more covariates) are common in health outcomes research in high prevalence, 
